Pfizer Resolves Trovan Litigation In Nigeria, But More Suits Remain
Executive Summary
Pfizer freed itself from the bulk of litigation over a 1996 Trovan clinical trial in Nigeria, agreeing to pay $75 million to settle civil and criminal charges brought by the Kano State government in Nigeria. The sum is a fraction of the more the $9 billion in claims the company was facing
You may also be interested in...
Out Of Africa: Why A Court Decision On Trovan Affects Pharma
Last month, a federal appeals panel jolted Pfizer by ruling that dozens of Nigerians can sue the drugmaker in a U.S. court over its handling of a 1996 clinical trial for its Trovan (trovafloxacin mesylate) antibiotic
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials